PT - JOURNAL ARTICLE AU - Marcus Carlsson AU - Gad Hatem AU - Cecilia Söderberg-Nauclér TI - Mathematical modeling suggests pre-existing immunity to SARS-CoV-2 AID - 10.1101/2021.04.21.21255782 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.21.21255782 4099 - http://medrxiv.org/content/early/2021/07/16/2021.04.21.21255782.short 4100 - http://medrxiv.org/content/early/2021/07/16/2021.04.21.21255782.full AB - Mathematical models have largely failed to predict the unfolding of the COVID-19 pandemic. We revisit several variants of the SEIR-model and investigate various adjustments to the model in order to achieve output consistent with measured data in Manaus, India and Stockholm. In particular, Stockholm is interesting due to the almost constant NPI’s, which substantially simplifies the mathematical modeling. Analyzing mobility data for Stockholm, we argue that neither behavioral changes, age and activity stratification nor NPI’s alone are sufficient to explain the observed pandemic progression. We find that the most plausible hypothesis is that a large portion of the population, between 40 to 60 percent, have some protection against infection with the original variant of SARS-CoV-2.Competing Interest StatementCSN has submitted a patent application for discovery of pre-existing immunity of Inluenza A possibly important for SARS-CoV-2Funding StatementThis work was supported by the Swedish Medical Research Council (2019-01736).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB was approved by the Swedish Ethical Authority (2020-06333).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code will be made available on github once the manuscript is accepted for publication.